FR08C0001I1 - - Google Patents
Info
- Publication number
- FR08C0001I1 FR08C0001I1 FR08C0001C FR08C0001I1 FR 08C0001 I1 FR08C0001 I1 FR 08C0001I1 FR 08C0001 C FR08C0001 C FR 08C0001C FR 08C0001 I1 FR08C0001 I1 FR 08C0001I1
- Authority
- FR
- France
- Prior art keywords
- formulation
- deslorelin
- mug
- testosterone
- cats
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
A pharmaceutical and/or veterinary formulation comprising deslorelin and an excipient, the formulation being characterised in that, in vitro, it releases deslorelin into phosphate buffered saline, as hereinbefore described, at 37° C. at a rate of about 2-80 mug/day for at least 200 days. The formulation may be used for prevention of reproductive function, particularly in dogs and cats, and for the treatment, particularly in humans, of prostate and breast cancer and other diseases and conditions where suppression of testosterone or estradiol levels is beneficial.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN3667A AUPN366795A0 (en) | 1995-06-20 | 1995-06-20 | Formulation for preventing reproductive function |
| PCT/AU1996/000370 WO1997000693A1 (en) | 1995-06-20 | 1996-06-20 | Novel formulation for peptide release |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR08C0001I1 true FR08C0001I1 (en) | 2008-03-21 |
| FR08C0001I2 FR08C0001I2 (en) | 2009-11-20 |
Family
ID=3788008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR08C0001C Active FR08C0001I2 (en) | 1995-06-20 | 2008-01-10 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US5925619A (en) |
| EP (1) | EP0871467B1 (en) |
| JP (1) | JP4016133B2 (en) |
| CN (1) | CN1145496C (en) |
| AT (1) | ATE223726T1 (en) |
| AU (2) | AUPN366795A0 (en) |
| CA (1) | CA2225796C (en) |
| DE (2) | DE122008000004I2 (en) |
| DK (1) | DK0871467T3 (en) |
| ES (1) | ES2182983T3 (en) |
| FR (1) | FR08C0001I2 (en) |
| HK (1) | HK1014874A1 (en) |
| NL (1) | NL300330I2 (en) |
| NZ (1) | NZ309697A (en) |
| PT (1) | PT871467E (en) |
| SI (1) | SI0871467T1 (en) |
| WO (1) | WO1997000693A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN366795A0 (en) * | 1995-06-20 | 1995-07-13 | Peptide Technology Limited | Formulation for preventing reproductive function |
| ATE359805T1 (en) | 1996-08-30 | 2007-05-15 | Peptech Ltd | SUSTAINED RELEASE FORMULATION OF GNRH PEPTIDE AGONISTS AND ANALOGS |
| US8052982B2 (en) * | 1998-07-20 | 2011-11-08 | Peptech Animal Health Pty Limited | Bioimplant formulation comprising lecithin and stearin |
| EP1104296B1 (en) * | 1998-07-20 | 2012-06-13 | Peptech Animal Health Pty Limited | Bioimplant formulation |
| US6211221B1 (en) * | 1999-04-05 | 2001-04-03 | Johnny W. Peterson | Dietary supplement containing histidine for alleviating dysmenorrhea, endometriosis, and pre-term labor |
| US7498303B2 (en) * | 2000-10-30 | 2009-03-03 | University Of Zuerich | GNRH analogues for treatment of urinary incontinence |
| GB0221539D0 (en) * | 2002-09-17 | 2002-10-23 | Medical Res Council | Methods of treatment |
| US20060003008A1 (en) * | 2003-12-30 | 2006-01-05 | Gibson John W | Polymeric devices for controlled release of active agents |
| WO2006071208A1 (en) * | 2004-12-23 | 2006-07-06 | Durect Corporation | Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of a gnrh |
| KR20100057050A (en) * | 2007-09-11 | 2010-05-28 | 몬도바이오테크 래보래토리즈 아게 | Use of a deslorelin and mastoparan as a therapeutic agent |
| DE102008015104A1 (en) | 2008-03-19 | 2009-09-24 | Basf Coatings Ag | Coating composition, process for its preparation, its use and substrates coated therewith |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS563846B2 (en) * | 1972-10-12 | 1981-01-27 | ||
| US4218439A (en) * | 1977-07-14 | 1980-08-19 | The Salk Institute For Biological Studies | Peptide which inhibits gonadal function |
| US4256737A (en) * | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
| CA1257199A (en) * | 1986-05-20 | 1989-07-11 | Paul Y. Wang | Preparation containing bioactive macromolecular substance for multi-months release in vivo |
| ES2039219T3 (en) * | 1986-08-11 | 1993-09-16 | American Cyanamid Company | COMPOSITIONS FOR PARENTERAL ADMINISTRATION AND ITS USE. |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| WO1993015722A1 (en) * | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| AUPN366795A0 (en) * | 1995-06-20 | 1995-07-13 | Peptide Technology Limited | Formulation for preventing reproductive function |
-
1995
- 1995-06-20 AU AUPN3667A patent/AUPN366795A0/en not_active Abandoned
-
1996
- 1996-06-20 WO PCT/AU1996/000370 patent/WO1997000693A1/en active IP Right Grant
- 1996-06-20 ES ES96917292T patent/ES2182983T3/en not_active Expired - Lifetime
- 1996-06-20 DE DE122008000004C patent/DE122008000004I2/en active Active
- 1996-06-20 DE DE69623652T patent/DE69623652T2/en not_active Expired - Lifetime
- 1996-06-20 CA CA2225796A patent/CA2225796C/en not_active Expired - Lifetime
- 1996-06-20 AU AU59927/96A patent/AU701837B2/en not_active Expired
- 1996-06-20 NZ NZ309697A patent/NZ309697A/en not_active IP Right Cessation
- 1996-06-20 US US08/981,285 patent/US5925619A/en not_active Expired - Lifetime
- 1996-06-20 PT PT96917292T patent/PT871467E/en unknown
- 1996-06-20 SI SI9630524T patent/SI0871467T1/en unknown
- 1996-06-20 DK DK96917292T patent/DK0871467T3/en active
- 1996-06-20 JP JP50345797A patent/JP4016133B2/en not_active Expired - Lifetime
- 1996-06-20 CN CNB961948647A patent/CN1145496C/en not_active Expired - Lifetime
- 1996-06-20 AT AT96917292T patent/ATE223726T1/en active
- 1996-06-20 EP EP96917292A patent/EP0871467B1/en not_active Expired - Lifetime
-
1999
- 1999-01-08 HK HK99100086A patent/HK1014874A1/en not_active IP Right Cessation
- 1999-02-17 US US09/251,411 patent/US6211152B1/en not_active Expired - Lifetime
-
2008
- 2008-01-08 NL NL300330C patent/NL300330I2/en unknown
- 2008-01-10 FR FR08C0001C patent/FR08C0001I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ309697A (en) | 1999-11-29 |
| NL300330I2 (en) | 2008-04-01 |
| AU701837B2 (en) | 1999-02-04 |
| CN1188414A (en) | 1998-07-22 |
| DE122008000004I1 (en) | 2008-04-17 |
| EP0871467A1 (en) | 1998-10-21 |
| PT871467E (en) | 2002-12-31 |
| JP2001521482A (en) | 2001-11-06 |
| DK0871467T3 (en) | 2002-12-23 |
| WO1997000693A1 (en) | 1997-01-09 |
| ATE223726T1 (en) | 2002-09-15 |
| DE69623652D1 (en) | 2002-10-17 |
| EP0871467B1 (en) | 2002-09-11 |
| SI0871467T1 (en) | 2003-08-31 |
| NL300330I1 (en) | 2008-03-03 |
| US6211152B1 (en) | 2001-04-03 |
| EP0871467A4 (en) | 2000-07-05 |
| AU5992796A (en) | 1997-01-22 |
| JP4016133B2 (en) | 2007-12-05 |
| CA2225796A1 (en) | 1997-01-09 |
| AUPN366795A0 (en) | 1995-07-13 |
| HK1014874A1 (en) | 1999-10-08 |
| ES2182983T3 (en) | 2003-03-16 |
| DE69623652T2 (en) | 2003-05-28 |
| CA2225796C (en) | 2011-09-20 |
| CN1145496C (en) | 2004-04-14 |
| FR08C0001I2 (en) | 2009-11-20 |
| DE122008000004I2 (en) | 2009-08-06 |
| US5925619A (en) | 1999-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR08C0001I2 (en) | ||
| AU4718496A (en) | Use of aerogels in agriculture | |
| AU560829B2 (en) | Continuous release pharmaceutical compositions | |
| PL313223A1 (en) | Nigella sativa as a therapeutic agent | |
| EP1178988A4 (en) | Compounds and therapeutic methods | |
| MY138883A (en) | Use of asiatic acid for treatment of cencer | |
| MY164077A (en) | Compositions and uses of et743 for treating cancer | |
| EP0663835A1 (en) | Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy. | |
| AU5673399A (en) | Compositions and methods for treating intracellular infections | |
| IL107153A (en) | Pharmaceutical compositions for preventing insulin-dependent diabetes mellitus comprising IL10 and method for their manufacture | |
| BR9607541A (en) | Treatment of diseases caused by the cytokine growth factor | |
| IL118218A0 (en) | Terpenoidic derivatives and pharmaceutical compositions containing them | |
| WO1994020115A3 (en) | Hyaluronic acid used as a cancer treatment | |
| OA09771A (en) | Asphodelus composition for increasing white blood cell count. | |
| BG51699A1 (en) | Stimulating fertility agent | |
| UA30723A (en) | method for treatment of autoimmune diseases | |
| MX9800697A (en) | Use of calendula glycosides for the treatment of psoriasis. | |
| MX9603535A (en) | Acidified nitrite as an antimicrobial agent. | |
| IT1243978B (en) | Drug for human use, of contraceptive and preventative oncostatic action, in tumours of the breast and the uterus and in melanoma | |
| UA36126A (en) | Lumbar bandage |